Paul Richardson, MD
Findings from the phase III OPTIMISMM trial established the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) as a new standard of care in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide (Revlimid), said Paul Richardson, MD.
, Richardson discussed the combination’s efficacy and tolerability, as well as the possibility of pairing PVd with other agents to boost outcomes without increasing toxicity in multiple myeloma.
OncLive: Can you discuss the background of this study?
We have demonstrated that there is synergy between immunomodulatory (IMiD) treatments and proteasome inhibitors. That's been a paradigm in myeloma treatment for some time.
We randomized about 570 patients across a large number of centers. It was a real global effort—there was a fantastic world partnership with colleagues in Europe, Canada, the United States, and all over the world.
What did you find when you looked at PFS?
What we saw, first and foremost, is that in fact, the PFS benefit with the 3 drugs over the 2 was quite striking and quite early.
... to read the full story